Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

J. Motzer, Robert; Escudier, Bernard; McDermott, Ray; George, Saby; J. Hammers, Hans; Srinivas, Sandhya; S. Tykodi, Scott; A. Sosman, Jeffrey; Procopio, Giuseppe; R. Plimack, Elizabeth; Castellano, Daniel; K. Choueiri, Toni; Gurney, Howard; Donskov, Frede; Bono, Petri; Wagstaff, John; Gauler, Thomas; Ueda, Takeshi; Tomita, Yoshihiko; A.B. Schutz, Fabio; Kollmannsberger, Christian; Larkin, James; Ravaud, Alain; S. Simon, Jason; Xu, Li-An; M. Waxman, Ian; Sharma, Padmanee

doi:10.1056/nejmoa1510665

Public

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Published in New England Journal of Medicine • Sep 25, 2015

Authors:

Robert J. Motzer

Bernard Escudier

Ray McDermott

Abstract

BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in...

Subject

Everolimus

Nivolumab

Renal cell carcinoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!